Biodegradable haemostatic therapeutic agent
SUBSTANCE: what is described is a biodegradable haemostatic therapeutic agent for control of bleeding, which provides co-immobilising ε-aminocapronic acid 50 mg, lysozyme 5 mg in distilled water 6.5 l for 3 hours at room temperature for dialdehyde cellulose 1 g at a degree of oxidation 12%. The material is pressed out and dried to residual moisture no more than 10% in the air in darkness. After having dried, the material is milled in a fine mill to particles having a size of 20 to 50 mcm. A rate of control of bleeding is 102 seconds. A time of total resorption is 10 days.
EFFECT: agent provides a high degree of hydrolytic destruction and a good haemostatic activity.
4 cl, 2 ex
The invention relates to a pharmacy, specifically to methods for hemostatic (hemostatic) drugs based on partially oxidized cellulose.
The above-mentioned drugs known. So, in the EPO application No. 1153620 described preventing bacterial infection in wounds hemostatic bandage from oxidized cellulose SURGICEL (firm "Johnson & Johnson"), containing from 1 to 10000 ppm of iron ions (3+), and from EPO application No. 0468114 known soluble hemostatic material in the form of webs of cellulose subjected to the oxidation of monochloracetic acid and sodium hypochlorite for introducing carboxyl groups COOH.
In the EPO application No. 0659440 describes a method for hemostatic based on oxidized cellulose containing 0.5-4.0% calcium and thrombin, fibrinogen and/or antifibrinolytic. The disadvantages of this method include the use of cellulose, mild oxidation of which with the transformation of CH2OH groups in the carboxyl (COOH), it is not possible to obtain a material that provides the possibility of a strong link with him ingredients: only the ions of Ca2+associated with COOH-groups of the ionic forces, while the remaining components are in the form of physical (mechanical) mixture. In addition, such materials are difficult to further grinding, for example, in Orasac (similar).
Known way to obtain a powdery material having hemostatic action, which comprises mixing in aqueous medium medium partially oxidized cellulose to valdecaballeros (DAC) with blood clotting factors, for example, thrombin and fibrinogen, to these substances additionally add gelatin, ε-aminocaproic acid and lysozyme, as well as partially oxidized cellulose use valdecaballeros in the form of a fabric having a degree of oxidation, i.e. the content of aldehyde groups, from 4 to 6%, with the following relations between the components:
- dialdehydes 1 g;
- fibrinogen 18/22 mg;
- gelatin 27/33 mg;
- ε-aminocaproic acid 45/55 mg;
- lysozyme 9,5/10,5 mg;
- thrombin 350 units;
- water and 6.5 ml
Components can withstand up to full covalent binding of drugs with dialdehydes with subsequent drying and grinding into powder. To prevent interaction of thrombin and fibrinogen the process of obtaining the drug lead in two stages. Separately prepare a solution of fibrinogen, ε-aminocaproic acid and half of the total amount of gelatin in half of the total amount of water and a solution of thrombin and lysozyme and the remaining amount of gelatin in the remaining amount of water in the obtained solutions as well who live within 3-4 hours by half the number of valdecaballeros, intermediates drained, dried in air and subjected to joint grinding. Time stop bleeding with this drug in the experiment was 110 sec, see, for example, patent RF №2235539, 2003(prototype).
The specified technical solution is not without flaws. First, the blood - thrombin and fibrinogen are very expensive and scarce. In addition, more patients in the world refuse to use drugs derived from animal organs and tissues or blood. Secondly, to avoid interaction in aqueous solution of thrombin and fibrinogen their immobilization are separated, then dried cloth and conduct joint grinding to powder. This adds cost and complexity to the process. The third drawback is the low degree of oxidation DAC, which leads to the slowing of the rate of hydrolytic degradation of the drug.
The present invention is to remedy these disadvantages and to obtain a powder of the biodegradable hemostatic drugs having a high degree of hydrolytic degradation (ability to complete desorption) and good hemostatic activity.
To this end substantially changed the composition of the medicinal components excluded expensive deficient blood and gelatin, significantly simplifies the technological process is to obtain medicines significantly increased oxidation DAC, which ultimately led to the accelerated hydrolytic degradation and, consequently, to reduce the time complete resorption while increasing hemostatic activity.
Additional studies have shown that increasing the degree of oxidation of valdecaballeros (DAC) and its protein derivative increases the rate of hydrolytic degradation. While proteins diffuse in the aquatic environment is not in the form of natural substances and in the form of conjugates with oligomers DAC, which makes them more resistant to inactivating factors (heat, pH of the medium, inhibitors) compared with native biologically active substances (BAS), i.e. show prolonged a specific action. The kinetics of hydrolytic degradation describes a semi-log anamorphosis and in logarithmic coordinates is a straight line, the tangent of the angle which quantitatively expresses the rate constant hydrolytic degradation as the reaction rate constant of the first order.
Knowing these constants, it is easy to calculate the half-life period (polarizable) drug by the formula
where K is the rate constant of destruction,
T/2 - time half-life of the drug.
Experimental data of the dependence of the rate constants for the hydrolytic degradation of the oxidation DAC are shown in table 1.
|Oxidation DAC, %||The rate constant hydrolytic distractie, min-1|
On the other hand, when increasing the degree of oxidation DAC sharply decreases its mechanical strength. The influence of the degree of oxidation of cellulose (medical gauze) to DAC on the strength characteristics of the material are presented in table 2.
|The degree of oxidation,%||Breaking load (on the base), Dan||The preservation of the breaking load, %|
From the data presented in tables 1 and 2, it follows that an increase in the oxidation rate of over 12% is irrational, because with only a slight increase in the rate constants of hydrolytic degradation, significant drop in mechanical strength DATS more than 50%. It should also be noted that when the grinding DAC high degrees of oxidation is formed dust fraction of the powder.
Comparative characteristics of the hemostatic properties of materials and their relationship to the degree of oxidation DAC, part time and full resorption are shown in table 3.
|Oxidation DAC,%||The coagulation factors, mg per 1 g DAC||Constant speed hydrolytical some of distractie||Time stop bleeding sec||
The full resorb-|
tion, of the day
|According to the patent of Russian Federation №2235539 4-6%, the placeholder||Fibrinogen 18-22 gelatin 27-23 aminocaproic acid 45-55 lysozyme 9,5-10,5 thrombin 350%||18×10-5min-1||110||20|
|On the proposed decision of 12%||Aminocaproic acid is introduced in a quantity of 50 mg/g, lysozyme - 5 mg/g||33×10-5min-1||102||10|
Thus, the proposed new biodegradative hemostatic drug in powder form with particle sizes from 20 to 50 μm has the following characteristics:
DAC with degrees of oxidation - 12% - 1.0 g;
ε-aminocaproic acid - 50,0±0.25 mg/g;
lysozyme - 5,0±0.25 mg/g
Medicinal composition, such composition provides a high speed stop bleeding, prolonged preservation of the sterility of the material and the minimum time to complete resorption.
Time stop bleeding - 102 sec.
The time of complete resorption to 10 days.
Therefore, the proposed solution meets all the requirements of the invention: novelty, usefulness and level of technology.
The novelty is ostoic, first, that for immobilization of hemostatic agents as media use DAC with the degree of oxidation of 12%. Secondly, as a specific hemostatic use ε-aminocaproic acid (without fibrinogen, thrombin and gelatin). Thirdly, the proposed composition is a fine powder with particle sizes from 20 to 50 μm. Fourthly, the time for complete resorption is 10 days.
The obvious usefulness: speed stop bleeding equal to 102 sec, which is less than, but comparable with the time stop bleeding prototype - 110 sec, but given that this is simple and few of the medicinal components of the composition, especially with the property biodegradation (resorption), the usefulness of this development is indisputable.
The level of technology
The drug is made Pharmacopeia and other documents required for inclusion in the Pharmacopoeia of the Russian Federation. No single product on the basis of DAC, previously permitted for medical use, has no such status.
The invention is illustrated in the examples.
In the reactor fill in 6.5 liters of distilled water, include the stirrer and add 185 g periodate sodium. The solution is stirred until complete dissolution of the reagent. In the resulting solution of periodate sodium is amemait 1 kg of cellulose (medical cotton gauze) in the form of cloth and incubated at room temperature in the dark for 14 hours. After activation, wring out the cloth, washed 4 times in 10 l of distilled water, again squeezed and dried in air in the dark to a residual moisture content of not more than 10% at room temperature. Oxidation of cellulose to DAC is 12%.
6.5 liters of distilled water dissolve 50 g of ε-aminocaproic acid, 5 g of lysozyme, the reaction mass is stirred, the pH of the solution to 5.5 to 6.0. The solution was placed 1 kg DAC with the degree of oxidation of 12%, incubated for 3 hours at room temperature in the dark, drained, dried in air in the dark to a residual moisture content of not more than 10% and ground in a mill, super thin grinding to a particle size of from 20 to 50 microns.
In experimental conditions in adult rabbits caused bleeding during intravenous injection of 500 IU of heparin and 250 fibrinolizina ED. Mechanically, the bleeding stopped after 20-30 minutes
Under hypentelium anesthesia superficial excision of the fragment liver size 1.4 cm2caused the bleeding, the wound was imposed biodegradative hemostatic agent, noting stop bleeding through 102 sec.
1. Biodegradative hemostatic drug in the form of microfiber, consisting of dialdehydes with chemically immobilized on the coagulation factor ε-aminocaproic KIS the Auteuil and bacteriolytic enzyme lysozyme,
characterized in that, as a partially oxidized cellulose it contains dialdehydes with the degree of oxidation of 12%, with the following components:
DAC with oxidation States 12% - 1.0 g;
ε-aminocaproic acid 50,0±0.25 mg/g;
lysozyme 5,0±0.25 mg/g
2. Biodegradative hemostatic medicinal product according to claim 1, characterized in that the particle sizes of its microfiber forms of partially oxidized cellulose with immobilized her components ranged from 20 to 50 microns.
3. Biodegradative hemostatic medicinal product according to claim 1, characterized in that the time of the full hydrolytic destruction - complete biodegradation is not more than 10 days.
4. Biodegradative hemostatic medicinal product according to claim 1, characterized in that the stop time of bleeding, its use is not more than 102 seconds.
SUBSTANCE: invention represents a biodegradable haemostatic therapeutic agent for bleeding. Using the prepared haemostatic agent according to the declared method provides a rate of control of bleeding making 45±2 seconds.
EFFECT: higher rate of control of bleeding.
4 cl, 2 tbl
SUBSTANCE: agent further contains aluminium and/or magnesium oxides and satisfies the formula: CaO·(SiO2)m·(M)n·(H2O)k, where M is Al2O3 and/or MgO; m=0.5-3.0; n=0.01-0.05; k=0.2-1.2.
EFFECT: shorter time for onset of hemostasis and low exothermic effect during interaction with blood.
2 tbl, 9 ex
SUBSTANCE: invention refers to medicine, namely to hematology and oncology, and concerns correction of amegakaryocytic thrombocytopenia. That is ensured by introducing a platelet concentrate and performing autologous peripheral haemopoietic stem cell transplantation with performing a single subcutaneous injection of romiplostim 200-300 mcg on the day of the transplantation.
EFFECT: method provides reducing a risk of the haemorrhagic complications following the high-dose chemotherapy, ensured by the fast and effective platelet growth.
2 ex, 1 tbl
SUBSTANCE: agent contains chitosan salt 75-95 wt % of polydisperse powders of chitosan hydrochloride, hydrobromide, formate, acetate, succinate, citrate, glycolate or lactate and polyhexamethylene guanidine hydrochloride 4-20 wt %. The chitosan salt and polyhexamethylene guanidine hydrochloride are covalently cross-linked by a polyfunctional compound 1-5 wt % of glycidyl ethers. The chitosan salt is specified with an average particle size of 0.2÷2.0 mm, degree of chitosan deacetylation 0.75÷0.95, and molecular weight 10÷500 kDa. The above polyfunctional compound of glycidyl ethers is presented by a diglycidyl ether of butandiol, di- or triethylene glycol or propylene glycol, oligoethylene oxide, as well as triglycidyl ethers of glycerol or trimethylol propane.
EFFECT: method possesses high blood sorption capacity, rapid hemostasis time and high antimicrobial activity.
3 cl, 2 tbl, 12 ex
SUBSTANCE: invention represents a hemostatic preparation containing a complex of aminocaproic acid and ferric iron stabilised with sodium chloride in the isotonic concentration. The invention aims at wound healing, small hemostasis at administering the first medical aid at the pre-hospital emergency evacuation.
EFFECT: what is provided is preparing the preparation very soluble in water and possessing high hemostatic activity, low costs and extended storage period.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture.
EFFECT: preparing the antiseptic drug with haemostatic action for wound cleaning.
2 cl, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics. There are developed agent for forming a biogel, biogels for hemostasis, wound closure, tissue engineering and targeted drug delivery. The agent contains a soluble carrier whereon a number of fibrinogen-binding groups is immobilised. The biogel that contains fibrinogen molecules and a number of soluble carriers applicable for intravenous and/or local administration; each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, and each fibrinogen molecule is bound to at least two fibrinogen-binding groups so that the fibrinogen molecules occurs to be bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen molecules. The biogel containing fibrin monomers and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, while the fibrin monomers are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. The biogel containing fibrin and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier with the fibrin monomers in fibrin are covalently bound to each other by peptide bonds, and the fibrin monomers in fibrin are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. A method for forming the biogel involving a contact of the fibrinogen molecules with a number of soluble carriers. A method for hemostasis by topical administration of the biogel at a haemorrhage or a wound. Using a number of soluble carriers applicable for intravenous and/or local administration. A pharmaceutical formulation for topical administration containing the biogel, agent or a number of soluble carriers.
EFFECT: using the declared invention enables preparing the agents requiring no toxic reagents to be used, have a minimal risk of allergic reactions, and are easy to prepare and use.
2 tbl, 4 dwg, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a haemostatic agent used in small cuts, characterized by the fact that it is represented in the form of a match with its head having the following formulation, wt %: sodium chloride - 0.58 - 0.71; ε-aminocaproic acid - 2.14 - 3.25; purified water - 60.93 - 73.98; aluminium potassium sulphate - 19.65 - 32.84; lanolin - 1.77 - 2.92.
EFFECT: invention provides creating the agent which has the non-burning haemostatic agent when applied on the small cuts.
SUBSTANCE: group of inventions refers to medicine and aims at conducting the endoscopic hemostasis in gastric-duodenal hemorrhages. For the purpose of conducting the hemostasis, the capillary hemostasis liquid "Hemostab" is used and accompanied by the injection compression infiltration of paravasal and periulcerous regions. "Hemostab" is introduced within a hemorrhage point that is followed by the argon-plasma coagulation.
EFFECT: using the declared group of inventions is effective for the hemostasis in gastric-duodenal hemorrhages; it has the positive local effect on the clinical course of the pathological process, reduces the length of recovery of the defects caused the hemorrhage with no toxicity of the above preparation and no allergies.
1 ex, 3 dwg, 6 cl
SUBSTANCE: group of inventions refers to medicine, particularly to treating hemophilia. The factor IX conjugates are modified to include a biocompatible polymer fragment. The factor IX conjugates are substantially free from the factor IXa contaminations. The factor IX conjugates have the improved pharmacokinetic properties such as an extended half-life.
EFFECT: group of inventions enabling reducing the dosage and rate of administration, and also reduces the risk of hemarthrosis, hemorrhage, gastrointestinal bleeding, and menorrhagia in mammals suffering hemophilia B.
30 cl, 4 dwg, 9 ex
SUBSTANCE: group of inventions refers to medicine, namely traumatology and surgery, and may be used for bleeding control. That is ensured by the use of a composition, as well as an adhesive material containing gelatin and transglutaminase wherein their relation is sufficient for bleeding control in a wound, and wherein said gelatin is not exposed to irreversible gel-formation and forms a solution with transglutaminase at temperature below natural one of a gel-sol junction of standard animal gelatin prepared from an animal source or representing recombinant gelatin or their combination.
EFFECT: use of the given inventions enables reducing time of bleeding control in the wound.
22 cl, 15 dwg, 12 tbl, 15 ex
SUBSTANCE: invention refers to medicine. What is described is a method for making a hydrocolloid bactericidal dressing with wound-healing and antimicrobial properties. The dressing represents a structure of a number of layers fastened to each other. The layer adjoining the wound represents a perforated polyethylene film; it is coated with a hydrocolloid plate of acryl compounds with added glycerol covered with a non-woven layer with deposited dialdehydecellulose microfibers with the immobilised enzyme lysoamidase. An upper protective layer represents a perforated polyethylene film.
EFFECT: dressing reduces length of wound healing, easily removed from the surface of purified wound causing no injuries and pain sensations in a patient.
6 cl, 2 tbl, 4 ex
SUBSTANCE: invention relates to medicine. Described is method of obtaining disposable atraumatic application, which includes oxidation of medical gauze with obtaining dialdehidecellulose, further immobilisation of medications on it, oxidation being carried out to 6.0+0.33% degree, after that, obtained mixture is grinded until microfibrous form, modified by medicinal components, is obtained, mixed with powder of gel-forming reagent, mixture is intensively mixed with water, then, solution is poured into forms, dried and obtained gel plates are connected with paper layers, made from wood cellulose, by sewing method.
EFFECT: application ensures accelerated purification of wounds from purulent-necrotic masses and reduction of wound-healing terms.
2 cl, 5 ex
SUBSTANCE: invention relates to field of medicine, namely to bandage materials for treatment of purulent and infected wounds, trophic ulcers and for prevention of suppurations of infected wounds. Wound bandage with antimicrobial properties contains textile carrier based on dialdehidecellulose (DAC) with immobilised protein-degrading enzyme and antimicrobial preparation. As antimicrobial preparation used is nanostructured bentonite powder, intercalated with ions of metals Ag+ or/and Cu2+, or/and Zn2+. Wound bandage has the following content of components in it, wt %: protein-degrading enzyme - 0.03-0.1, nanostructured bentonite powder, intercalated with ions of metals Ag+ or/and Cu2+, or/and Zn2+ - 2.0-10.0, dialdehidecellulose - the remaining part. Wound bandage has high antimicrobial properties with respect to wide spectrum of Gram-positive, Gram-negative bacteria for precessing and treatment of wounds with signs of pyoin-inflamatory process of various etiology.
EFFECT: synergetic interaction of applied in wound bandage composition biological and mineral components improves therapeutic properties of dressing.
7 cl, 2 tbl, 11 ex
SUBSTANCE: invention relates to medicine, more specifically the preparation of extensive long-term non-healing wounds to dermanaplasty requiring the use of plastic split-skin graft. The method consists of applying hemostatic dressings are applied Gemoteks on the wound for 2-3 minutes immediately after surgical treatment on the, in the first stage of wound healing process dressings are used (3-4 days) with the alternation of Atraumatic Tissue Activetex HL, Activetex HF and Activetex HVIT-complex, while on the second stage of wound healing process (2-3 days) tissues Activetex FOM and Activetex FHF are alternated. After the appearance of the boundary epithelialisation and wound cleansing free skin grafting with split-skin graft is performed in accordance with traditional techniques.
EFFECT: invention solves the problem of easier and cheaper method of treatment of extensive long-term non-healing wounds by reducing the time of preparation of the wound surface to dermanaplasty.
SUBSTANCE: invention refers to chemical-pharmaceutical industry. The material for haemostasis contains dialdehyde cellulose of the oxidation level 6.5±0.33% - 1 g, gelatinol 60±3 mg - (0.75 ml), ε-aminocapronic acid 50±0.25 mg, lysozyme 5±0.25 mg, water 5.75 ml. The method for making the textile material expressing haemostatic action consists that ε-aminocapronic acid, gelatinol and lysozyme are successively dissolved in the distilled water at room temperature. After said components are dissolved completely, the prepared solution is placed into dialdehyde cellulose solution of the oxidation level 6.5%±0.33% in the form of a cloth and kept for 2 hours. Then the cloth is wrung out, air-dried to residual humidity no more than 10% with cutting out napkins of weight approximately 1 g and dimensions 7.5×5.0 cm, then sealed in polyethylene bags and sterilised by gamma irradiation in a dose 25 kGy. Besides for haemostasis of irregularly shaped deep stab, missile and shell fragment wounds, the prepared material is ground in a rotor impact mill to lint condition (cotton wool).
EFFECT: making the effective styptic (haemostatic) product of partially oxidised cellulose.
1 tbl, 5 ex, 3 cl
SUBSTANCE: present invention concerns medicine, particularly, to the substrate treated with bound enzyme. The substrate treated with bound enzyme, can be effective for improvement of ability of a substrate to absorb viscoelastic materials, such as menstrual secretion, by splitting of the albuminous structure containing in some viscoelastic materials. Besides, in comparison with a case of applying of enzyme immediately on a substrate, there is less probability that the bound enzyme will move from the treated material on the user, which reduces risk of sensibilisation of the user of an absorbing product. The invention also concerns absorbing products which contain at least one surface or layer containing bound enzyme.
EFFECT: development of absorbing products which contain at least one surface or layer containing bound enzyme.
20 cl, 3 dwg, 2 tbl, 2 ex
SUBSTANCE: invention concerns medicine and claims therapeutic material and therapeutic media based on it for purulo-necrotic wound treatment, as well as method of obtaining therapeutic material. Material includes activated textile carrier with trypsin, insulin and lysocim immobilised in it.
EFFECT: significant reduction of wound surface cleaning time, accelerated healing.
17 cl, 2 tbl, 9 ex
SUBSTANCE: invention concerns medicine, particularly media of surfacial wound and burn treatment, and can be applied in surgery, traumatology, therapy, ophthalmology, veterinary and adjoining fields. Wound healing medium is superexpanding polymer matrix including collagenase in amount of 1-10 wt % of matrix weight. Superexpanding polymer matrix is a matrix obtained by copolymerisation of at least two monomers of group including maleic, crotonic and acrylic acids and/or their derivatives in the presence of binding agent.
EFFECT: efficient wound healing agent viable for composition standardisation.
5 cl, 3 tbl, 4 ex
SUBSTANCE: medical bandage from chemically modified cellulose, which contains the immobilized chitosan, and which has the enzymes attached to it via chemical bonds, among those proteolytic, elastolytic and collagenolytic that constitute the enzyme complex of crab hepatopancreas. Also, the method of bandage preparation is described.
EFFECT: medical bandage shows improved mechanical properties.
2 cl, 1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmacy and medicine, and concerns a composition, a method and a kit which enable a controlled release of octreotide, e.g. octreotide acetate in an individual. The composition contains a preparation containing octreotide basically enclosed in a hydrophilic polymer specified in polyurethane polymers and methacrylate polymers; it is effective for providing octreotide release at a rate of 30 mcg to 800 mcg a day for six months in vivo, wherein the hydrophilic polymer, but not the preparation, additionally contains a releasing substance with molecular weight of at least approximately 1,000 Dalton, wherein the preparation contains octreotide 40 to 120 mg, and the releasing substance is specified in a group consisting of Brij 35 (polyoxyethylene lauryl ester), polyoxyethylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS and mixtures of any of the two or more.The method for reducing GH levels or IGF-1 levels and/or treating an octreotide-sensitive disease involving a subcutaneous implantation of at least one dry implanted device comprising the declared preparation. The kit comprising the declared composition for octreotide controlled release.
EFFECT: group of inventions provides a therapeutically effective amount of octreotide for a long period of time with treating hormonal conditions.
25 cl, 11 ex, 7 tbl, 21 dwg